CHICAGO — A transcatheter aortic valve implantation (TAVI) device developed specifically for the treatment for aortic regurgitation has met all the prespecified safety and efficacy goals, so far, in ...

ATLANTA, GA—Once again TAVI has proved noninferior to surgical aortic valve replacement for patients at low or intermediate risk with regard to all-cause death or stroke at 1 year, according to new ...

The investigational transcatheter aortic valve implantation (TAVI) system will complement Abbott's Navitor™ TAVI system for aortic stenosis, a common and life-threatening heart valve disease The ...

LONDON, England—Having a small or large annuli does not appear to make a difference for low-risk patients with symptomatic severe aortic stenosis, who have similar 5-year clinical and quality-of-life ...

CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...

The CE Mark pivotal study is ongoing, and 120 patients are planned to be enrolled. In Barcelona, Treede reported on the first 61 patients to receive the valve, although one did not receive the Engager ...

Abbott said it is building the foundation for artificial intelligence-guided procedures with its new transcatheter aortic valve implantation (TAVI) balloon-expandable system. This effort could help ...

Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were ...

Private company Colibri Heart Valve LLC reported the first two enrollees in the clinical early feasibility study of its second-generation expandable 24 mm and 27 mm transcatheter aortic valve (TAVI) ...

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were ...